The Overweight rating and price target of $58 by Piper Sandler analyst Do Kim indicate a positive outlook for Ionis Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it suggests that the analyst believes the stock is undervalued and has potential for growth.